SuperworthTG Therapeutics shares outstanding TGTX
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 157.3M
- On a year earlier
- −3.2%
- fewer shares
TG Therapeutics had 157.3M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 3.2% fewer than a year earlier, so each share owns a little more of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 159.4M | −1% |
| FY2024 | 160.2M | +12% |
| FY2023 | 143.1M | +4% |
| FY2022 | 137.1M | +3% |
| FY2021 | 132.6M | +7% |
| FY2020 | 124.1M | +30% |
| FY2019 | 95.7M | +22% |
| FY2018 | 78.6M | +18% |
| FY2017 | 66.6M | +35% |
| FY2016 | 49.3M | +2% |
| FY2015 | 48.1M | +24% |
| FY2014 | 38.9M | +32% |
| FY2013 | 29.4M | +49% |
| FY2012 | 19.7M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 157.3M | −3% | |
| Q1 FY26 | 160.1M | −2% | |
| Q4 FY25 | 159.4M | −1% | |
| Q3 FY25 | 161M | +0% | |
| Q2 FY25 | 162.6M | +2% | |
| Q1 FY25 | 162.8M | +11% | |
| Q4 FY24 | 160.2M | +12% | |
| Q3 FY24 | 160.7M | +3% | |
| Q2 FY24 | 159.4M | +13% | |
| Q1 FY24 | 146.2M | +4% | |
| Q4 FY23 | 143.1M | +4% | |
| Q3 FY23 | 155.9M | +15% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on TG Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.